Status:
ACTIVE_NOT_RECRUITING
Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Advanced Solid Tumors
Eligibility:
All Genders
18-100 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to continue to assess safety and tolerability, and to allow continued access to study treatment for subjects already receiving spartalizumab as single agent or in combinat...
Eligibility Criteria
Inclusion
- Subject is currently enrolled in a pre-defined Novartis-sponsored study and is receiving spartalizumab as single agent or in combination with other study treatment,
- Subject is currently deriving clinical benefit from the study treatment, as determined by the investigator.
- Other protocol defined inclusion criteria may apply
Exclusion
- Subject has been permanently discontinued from spartalizumab in the parent protocol for any reason other than enrollment in the Roll over Study
- Subject does not meet the criteria specified in the parent protocol criteria for continued study treatment.
Key Trial Info
Start Date :
October 30 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 30 2030
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT04058756
Start Date
October 30 2019
End Date
April 30 2030
Last Update
October 7 2025
Active Locations (48)
Enter a location and click search to find clinical trials sorted by distance.
1
Columbia University Medical Center
New York, New York, United States, 10032
2
Providence Portland Medical Center
Portland, Oregon, United States, 97123
3
MD Anderson Cancer Center Uni of Te
Houston, Texas, United States, 77030
4
Novartis Investigative Site
Leuven, Belgium, 3000